ABSTRACT
Background Intra-articular facet joint injection (FJI) has been increasingly used as a treatment for chronic low back pain (LBP). Choice of the substance has been based on clinical experience with unclear evidence on marginal effectiveness of active substance over normal saline as a placebo control. This systematic review investigates the comparative effectiveness between normal saline and active substances on patient-reported outcomes (PROs).
Methods Systematic search was conducted in five databases: PubMed, Embase, Scopus, Web of Science, and CENTRAL for randomized controlled trials and observational studies of evaluating the PROs of FJI comparing active injected substances with normal saline as placebo in chronic LBP patients in the English language without publication date restriction. Quality assessment was performed using ROB2 and ROBINS-I. The meta-analysis was done using a random-effects model. Mean difference with 95% CIs of efficacy outcomes including pain, numbness, disability, quality of life were measured.
Results Of 2,467 potential studies, three were included in the systematic review and meta-analysis (247 patients). Compared to other active substances, normal saline provided similar therapeutic effects on pain outcome within one hour (MD 2.43, 95% CI –11.61 to 16.50), at 1–1.5 months follow up (MD –0.63, 95% CI –7.97 to 6.72), and at 3 to 6 months (MD 1.90, 95% CI –16.03 to 19.83) as well as the quality of life at one and six months follow-up.
Conclusions The short-term and long-term clinical improvements of intra-articular FJI using normal saline are comparable to the other active substances in LBP patients.
PROSPERO registration number CRD42020216426
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
PROSPERO registration number CRD42020216426
Funding Statement
The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(tnopsopon{at}gmail.com)
(doctorkrit{at}gmail.com)
(thanitsara.r{at}gmail.com)
(i.lertparinyaphorn{at}gmail.com)
(rehabchula{at}gmail.com)
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.